Document is current
Any future updates will be listed below
-
Authors
Bar-Zeev, Yael
Levine, Hagai
Rubinstein, Gil
Khateb, Ihab
Berg, Carla J. https://orcid.org/0000-0001-8931-1961
-
Funding
Funding for this research was provided by:
Division of Cancer Prevention, National Cancer Institute (R01CA179422-01, R01CA215155-01A1)
Fogarty International Center (R01TW010664-01)
- License Information
-
More Information
Article History
Received: 26 September 2018
Accepted: 18 December 2018
First Online: 14 January 2019
Ethics approval and consent to participate
: Emory University’s Institutional Review Board indicated this study was exempt, as no human subjects were involved.
: N/A.
: Yael Bar-Zeev has received fees for lectures from Pfizer Ltd (distributor of a smoking cessation pharmacotherapy in Israel) in 2012-2015 and 2017-current. She has also received fees for lectures from Novartis (past distributor of nicotine replacement therapy in Israel) in the past (2012-2015). Hagai Levine had received fees for lectures from Pfizer Israel Ltd (distributor of a smoking cessation pharmacotherapy in Israel) in 2017. Carla Berg declares no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
